Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) filed a 424B3 prospectus — a supplement filed under an already-effective registration statement — on July 20, 2026, covering up to 2,942,400 shares for resale by selling stockholders. Those shares are eligible to reach the public market immediately, at the holders' discretion.

The scale of the registered supply is significant. The 2,942,400 shares represent roughly 49% of the company's 3,098,592 post-issuance shares outstanding, meaning the resale pool is nearly as large as the entire existing share count.

Structure of the PIPE

The shares stem from a PIPE — a private investment in public equity — placed through H.C. Wainwright with Armistice Capital as the counterparty. The deal has two components:

• Pre-funded warrants, which are warrants exercisable at a nominal price (typically $0.001 per share), effectively making them free shares that can convert at any time with no meaningful additional cost to the holder.
• Series C-1 and C-2 warrants issued on a 1:1 basis, carrying an exercise price of $3.00 per share. These warrants include Black-Scholes cash-settlement rights on fundamental transactions — meaning that in a merger, acquisition, or similar corporate event, the warrant holder can demand a cash payout based on a theoretical option-pricing model rather than simply exercising the warrants for stock.

Repeat-Dilution Pattern

This is the fifth Wainwright-placed dilutive financing for CVKD in approximately three years. The sequence stretches from a July 2023 private placement through a November 2024 warrant inducement, December 2025 offerings, an April 2026 inducement, and now the July 2026 PIPE. Across those transactions, prior warrant exercise prices have been repriced downward from $16.50 to $4.50 — a pattern of successive resets that has steadily lowered the cost basis for institutional warrant holders.

Structural Red Flags

Several features amplify the dilution mechanics. The filing carries variable-price characteristics with no disclosed floor price, meaning there is no stated minimum at which shares can be issued or warrants reset. The warrants also include cashless exercise provisions — allowing conversion into shares without any cash payment to the company, which adds to share supply without adding to its treasury. The deal does include a one-year prohibition on variable-rate transactions, temporarily limiting the company's ability to enter additional financings with floating conversion prices.

What to Watch

Because the 424B3 was filed under an already-effective shelf registration, the 2,942,400 resale shares are free to trade now. Armistice Capital, as the selling stockholder, can liquidate at its discretion — supply will flow into the market incrementally rather than in a single block. Investors tracking float expansion should watch for Form 4 filings from Armistice, which would signal when and at what pace those shares are entering the market.